Why These 15 Healthcare Stocks Are Surging in 2025

Page 6 of 14

9. Palvella Therapeutics Inc (NASDAQ:PVLA)

Number of Hedge Fund Holders In Q4 2024: 9

Palvella Therapeutics Inc (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company developing and commercializing novel therapies for serious, rare genetic skin diseases that currently have no FDA-approved treatments.

The stock is up significantly so far in 2025 due to the February 2025 announcement that Palvella expanded its Phase 3 SELVA trial of QTORIN rapamycin to include younger patients aged 3 to 5 years, which broadened the potential patient population and increased investor optimism.

Earlier, Palvella reported exceptionally positive results from its Phase 2 trial of QTORIN rapamycin for microcystic lymphatic malformations, where 100% of participants were rated as “Much” or “Very Much” improved by clinicians, fueling further enthusiasm.

In March 2025, the company completed a merger and a $78.9 million private placement, which strengthened its balance sheet and enabled rapid advancement of its clinical pipeline. The company also initiated a Phase 2 trial (TOIVA) for QTORIN rapamycin in cutaneous venous malformations, with top-line results expected by late 2025.

The consensus price target of $44.43 implies 74.96% upside.

PVLA stock is up 111.58% year-to-date.

Page 6 of 14